Zymeworks Appoints Former Royalty Pharma SVP Kristin Stafford as CFO
Zymeworks appointed Kristin Stafford as CFO effective April 1, 2026, bringing finance leadership experience from Royalty Pharma where she led strategic planning and major capital market transactions. Stafford’s track record in disciplined capital allocation and complex deals supports Zymeworks’ asset and royalty aggregation strategy and pipeline advancement.
1. CFO Appointment and Background
Zymeworks, effective April 1, 2026, named Kristin Stafford as Chief Financial Officer. Stafford joins from Royalty Pharma plc where she served as Senior Vice President, Chief Accounting Officer since 2018 and previously led finance for BioPharma Credit plc, bringing extensive experience in strategic planning, disciplined capital allocation and major capital markets transactions.
2. Strategic Impact on Financial Operations
Stafford’s expertise in executing complex deals and managing external SEC reporting is expected to strengthen Zymeworks’ asset and royalty aggregation strategy, optimizing cash flows from licensed products such as Ziihera. Her leadership is anticipated to support disciplined capital deployment and drive long-term value creation as the company advances its biotherapeutics pipeline.